Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ash Bullement

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 2, 2020
"Stick or Twist?" Negotiating Price and Data in an Era of Conditional ApprovalDaniel Gladwell, Ash Bullement, Warren Cowell, et al.
Pharmacoeconomics - Open|July 8, 2019
Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health DataAsh Bullement, Samuel Thomas McMordie, Anthony James Hatswell, et al.
Pharmacoeconomics|July 28, 2018
Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort ModelsAnthony J Hatswell, Ash Bullement, Andrew Briggs, et al.
Pharmacoeconomics|June 29, 2019
NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care ExcellenceAsh Bullement, Matthew Taylor, Sam Thomas McMordie, et al.
BMC Medical Research Methodology|May 8, 2020
Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selectionAsh Bullement, Anna Willis, Amerah Amin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 6, 2022
Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1Sachin Vadgama, Jess Mann, Zahid Bashir, et al.
Open Access Rheumatology : Research and Reviews|September 17, 2021
An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)Ash Bullement, Emma S Knowles, Merel Langenfeld, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 1, 2023
A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology AssessmentAsh Bullement, Matthew D Stevenson, Gianluca Baio, et al.
Pharmacoeconomics|July 28, 2023
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis-Modeling Approach and ValidationPeter Gal, Gyorgyi Feldmajer, Margarida Augusto, et al.
Future Oncology (London, England)|April 28, 2023
A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancersLeanne Hamerton, Kelly Gomes, Ronan Fougeray, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 2, 2020
"Stick or Twist?" Negotiating Price and Data in an Era of Conditional ApprovalDaniel Gladwell, Ash Bullement, Warren Cowell, et al.
Pharmacoeconomics - Open|July 8, 2019
Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health DataAsh Bullement, Samuel Thomas McMordie, Anthony James Hatswell, et al.
Pharmacoeconomics|July 28, 2018
Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort ModelsAnthony J Hatswell, Ash Bullement, Andrew Briggs, et al.
Pharmacoeconomics|June 29, 2019
NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care ExcellenceAsh Bullement, Matthew Taylor, Sam Thomas McMordie, et al.
BMC Medical Research Methodology|May 8, 2020
Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selectionAsh Bullement, Anna Willis, Amerah Amin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 6, 2022
Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1Sachin Vadgama, Jess Mann, Zahid Bashir, et al.
Open Access Rheumatology : Research and Reviews|September 17, 2021
An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)Ash Bullement, Emma S Knowles, Merel Langenfeld, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 1, 2023
A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology AssessmentAsh Bullement, Matthew D Stevenson, Gianluca Baio, et al.
Pharmacoeconomics|July 28, 2023
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis-Modeling Approach and ValidationPeter Gal, Gyorgyi Feldmajer, Margarida Augusto, et al.
Future Oncology (London, England)|April 28, 2023
A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancersLeanne Hamerton, Kelly Gomes, Ronan Fougeray, et al.
Pageof 3